Regeneron Pharmaceuticals Inc. (Regeneron)

Lobbying Organisation Regeneron Pharmaceuticals Inc.

Date published 28 Aug, 2026

Relevant Matter Legislation

Public Policy Area Health

Period 1 May. 2026 to 31 Aug. 2026

Specific Details European Commission's proposed Biotech Act and the European Health Data Space

Intended results Sharing views on strengthening Europe's clinical trial framework.

Name of person primarily responsible for lobbying on this activity John Coughlan

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) Yes

Current or Former Designated Public Official(s)

John Coughlan (Former DPO) Special Adviser (Department of Defence)

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (1)

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Sean Kelly MEP (European Parliament)